Tag Archives: medicine

Do spinal cord injuries cause subsequent brain damage?

The research, published recently in two articles, one in of the Journal of Neuroscience, the other in Cell Cycle, highlights the close links between spinal cord injury and loss of brain function, and suggests potential treatment to prevent such changes. “Animal studies have shown that traumatic brain injury, even mild repeated injuries, can result in progressive brain tissue damage and cognitive decline, as well as widespread brain inflammation. But little research has examined whether these problems occur after spinal cord injuries,” said UM SOM anesthesiology professor and noted neurobiologist Alan Faden, MD, who led the study. “Our studies the first to show that isolated SCI can cause progressive loss of brain cells in key brain regions,” said Faden. …

Key mechanism, potential target to prevent leukemia found

The studies, in animal models, could lead to new effective treatments for leukemias that are resistant to chemotherapy, said Reuben Kapur, Ph.D., Freida and Albrecht Kipp Professor of Pediatrics at the Indiana University School of Medicine. The research was reported today in the journal Cell Reports. “The issue in the field for a long time has been that many patients relapse even though chemotherapy and other currently available drugs get rid of mature blast cells quite readily,” Dr. Kapur said, referring to the cancerous cells that overrun the blood system in leukemia. …

New imaging technique identifies receptors for targeted cancer therapy

“Protein overexpression is a hallmark of certain cancers and is used in clinical oncology to personalize treatment through tumor detection, molecular therapies, and therapeutic monitoring,” said lead author Kimberley S. Samkoe, assistant professor of Surgery at the Geisel School of Medicine and adjunct assistant professor at Thayer School of Engineering. “Protein expression is currently measured through a total protein analysis of tumor tissue. This new technique allows us to accurately determine the amount of protein receptors available for binding a drug without invasive biopsy.” The researchers developed a dual-tracer in vivo receptor concentration imaging (RCI) technique that involves the simultaneous injection of both a targeted and a non-targeted imaging agent. …

Scoring scheme predicts ability of cancer cells to spread to other parts of body

Led by Professor Jean Paul Thiery, Senior Principal Investigator, and Dr Ruby Huang, Principal Associate, both from CSI Singapore, the scientists developed a scoring scheme which monitors the epithelial-mesenchymal transition (EMT) mechanism. This process was shown to play a role in a large number of cancer-related events, including cancer invasion, metastasis, and chemo-resistance…

Promising anti-cancer activity in experimental drug: Next-gen melanoma drug, TAK-733, excels in lab tests

“The importance of this molecule is that it’s a next-generation and highly potent inhibitor of a known melanoma pathway. It was highly effective against melanoma and the method of our study — using patient-derived tumor samples grown in mice — makes us especially optimistic that we should see similar results in the human disease,” says John Tentler, PhD, investigator at the CU Cancer Center, associate professor at CU School of Medicine and one of the paper’s lead authors…

Scientists challenge efficacy of folfiri in a colorectal cancer subtype

Conclusions from the analysis, led by Manuel Hidalgo, Director of the Clinical Research Programme at CNIO, are in response to previous work published in the same journal in March, 2014 (Sadanandam et al). By means of analysing gene expression profiles, Sadanandam’s team designed a classification for colon cancer based on five subtypes, associating one of them, the stemlike subtype, with a better drug response to FOLFIRI; the standard treatment for this tumour type. Specifically, in a 21-patient group, 7 were classified as this subtype, 5 of whom (70%) exhibited a positive response to FOLFIRI. The authors of this article therefore concluded that the classification based on gene expression profiles is directly related to the drug response…

Novel molecular imaging drug offers better detection of prostate cancer

Prostate cancer is the most commonly diagnosed non-skin cancer in the United States, and it is second only to lung cancer as the leading cause of cancer deaths in American men. An estimated 233,000 new cases of prostate cancer will be diagnosed in the United States in 2014, and an estimated 29,000 will die of the disease. More than 2 million men are currently living with prostate cancer in the United States…